GlobeNewsWire
07 Dec 2025, 23:15 UTC · 41w ago
Verdict
Headline takes no side. We score IMMX +1.00 across three claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Immix Biopharma's NXC-201 demonstrated a 75% complete response (CR) rate in Phase 2 trials for relapsed/refractory AL Amyloidosis, with a potential future CR rate of 95%.
So whatA 75-95% CR rate is clinically transformative compared to the cited current treatment benchmark of 10% or lower, significantly increasing the likelihood of regulatory success.
More positive than 99% of claims this week
The company plans to submit a Biologics License Application (BLA) for NXC-201 in 2026 following the final NEXICART-2 readout.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 92% of claims this week
Clinical data reported no neurotoxicity and only low-grade cytokine release syndrome with a median duration of one day.
More positive than 86% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The company reported positive Phase 2 clinical results for NXC-201 with a high complete response rate and is advancing toward BLA submission.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
10h ago
+114.4%
Price agrees with the score
$11.92 vs $5.56 close before publication (Dec 5) · not market-adjusted
IMMX chart →
